Radiogenomic analysis demonstrates associations between 18F-Fluoro-2- Deoxyglucose pet, prognosis, and epithelial-mesenchymal transition in non-small cell lung cancer

Radiology

Volumn 280, Issue 1, 2016, Pages 261-270

  Yamamoto, Shota ^a   Huang, Danshan ^a   Du, Liutao ^a   Korn, Ronald L ^c   Jamshidi, Neema ^a   Burnette, Barry L ^a   Kuo, Michael D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c Scottsdale Medical Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; HEXOKINASE; MESSENGER RNA; MITOXANTRONE; PACLITAXEL; TUMOR MARKER; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL MIGRATION; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SPECIFIC SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENOMICS; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOGENOMIC ANALYSIS; VALIDATION STUDY; VERY ELDERLY; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORODEOXYGLUCOSE F18; GENOMICS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84975283406     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016160259     Document Type: Article

References (58)

1. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361(1):32-39.
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324(5930):1029-1033.
3. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55(1):79-87.
4. Demura Y, Tsuchida T, Ishizaki T, et al. 18FFDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44(4):540- 548.
5. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progressionfree survival in Hodgkin lymphoma. Blood 2006;107(1):52-59.
6. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44(2):224- 239.
7. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46(7):1144-1150.
8. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759.
9. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in nonsmall cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3(1):6-12.
10. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130(1):151-159.
11. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axisof evil in the war on cancer. Oncogene 2010;29(34):4741-4751.
12. Kang Y, Massagué J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004;118(3):277-279.
13. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9(4):265-273.
14. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9(6):582-589.
15. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449(7163):682-688.
16. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009;119(6):1417-1419.
17. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13(2):97-110.
18. Cicchini C, Laudadio I, Citarella F, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res 2008;314(1):143-152.
19. Mani SA, Guo W, Liao MJ, et al. The epithelial- mesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704-715.
20. Soltermann A, Tischler V, Arbogast S, et al. Prognostic significance of epithelialmesenchymal and mesenchymal-epithelial transition protein expression in non- small cell lung cancer. Clin Cancer Res 2008;14(22):7430-7437.
21. Jamshidi N, Jonasch E, Zapala M, et al. The radiogenomic risk score: construction of a prognostic quantitative, noninvasive imagebased molecular assay for renal cell carcinoma. Radiology 2015;277(1):114-123.
22. Jamshidi N, Jonasch E, Zapala M, et al. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol 2015 Nov 11. [Epub ahead of print].
23. Yamamoto S, Maki DD, Korn RL, Kuo MD. Radiogenomic analysis of breast cancer using MRI: A preliminary study to define the landscape. AJR Am J Roentgenol 2012;199(3):654-663.
24. Yamamoto S, Korn RL, Oklu R, et al. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 2014;272(2):568-576.
25. Yamamoto S, Han W, Kim Y, et al. Breast cancer: Radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis. Radiology 2015;275(2):384- 392.
26. Jamshidi N, Diehn M, Bredel M, Kuo MD. Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 2014;270(1):1-2.
27. Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25(6):675-680.
28. Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105(13):5213- 5218.
29. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(7):821-831.
30. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50(5):682-687.
31. Imsande HM, Davison JM, Truong MT, et al. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with headand- neck non-squamous cell carcinoma. AJR Am J Roentgenol 2011;197(4):976-980.
32. Shiono S, Abiko M, Okazaki T, Chiba M, Yabuki H, Sato T. Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg 2011;40(5):1165-1169.
33. Shiono S, Yanagawa N, Abiko M, Sato T. Noninvasive differential diagnosis of pulmonary nodules using the standardized uptake value index. Ann Thorac Cardiovasc Surg 2015;21(3):236-241.
34. Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging 2014;41(11):2154.
35. Park HH, Park DS, Kweon DC, et al. Intercomparison of 18F-FDG PET/CT standardized uptake values in Korea. Appl Radiat Isot 2011;69(1):241-246.
36. Gevaert O, Xu J, Hoang CD, et al. Non- small cell lung cancer: Identifying prognostic imaging biomarkers by leveraging public gene expression microarray data- methods and preliminary results. Radiology 2012;264(2):387-396.
37. Nair VS, Gevaert O, Davidzon G, et al. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 2012;72(15):3725-3734.
38. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98(9):5116-5121.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57(1):289- 300.
40. Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-smallcell lung cancer including stage IA patients. J Thorac Oncol 2014;9(1):59-64.
41. Sun Y, Daemen A, Hatzivassiliou G, et al. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab 2014;2(1):20.
42. Schmittgen TD, Livak KJ. Analyzing realtime PCR data by the comparative C(T) method. Nat Protoc 2008;3(6):1101-1108.
43. Zou C, Wang Y, Shen Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J Biochem Biophys Methods 2005;64(3):207-215.
44. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20(9):1453-1454.
45. Saldanha AJ. Java TreeView-extensible visualization of microarray data. Bioinformatics 2004;20(17):3246-3248.
46. Gill BJ, Gibbons DL, Roudsari LC, et al. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res 2012;72(22):6013- 6023.
47. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139.
48. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11(24 Pt 1): 8686-8698.
49. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148(1-2):349- 361.
50. Sánchez-Tilló E, Fanlo L, Siles L, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ 2014;21(2):247-257.
51. Kajiwara T, Hiasa Y, Nishina T, et al. Maximum standardized uptake value in (18) F-fluoro-2-deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer. Mol Clin Oncol 2014;2(2):313-321.
52. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008;29(12): 2267-2278.
53. Yang MH, Wu MZ, Chiou SH, et al. Direct regulation of TWIST by HIF-1a promotes metastasis. Nat Cell Biol 2008;10(3):295-305.
54. Guillaumond F, Leca J, Olivares O, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2013;110(10):3919- 3924.
55. Fischer KR, Durrans A, Lee S, et al. Epithelial to mesenchymal transition is not required for breast to lung metastasis but contributes to chemoresistance. Cancer Res 2015;75(15 Supplement):4721.
56. Fischer KR, Durrans A, Lee S, et al. Epithelial- To-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527(7579):472- 476.
57. Zheng X, Carstens JL, Kim J, et al. Epithelial- To-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527(7579):525-530.
58. Meng F, Speyer CL, Zhang B, et al. PDGFRa and b play critical roles in mediating Foxq1- driven breast cancer stemness and chemoresistance. Cancer Res 2015;75(3):584-593.